Association Between Human Papillomavirus and Chlamydia Trachomatis Infection Risk in Women: a Systematic Review and Meta-analysis

Overview

Journal Int J Public Health

Specialty Public Health

Date 2019 Jun 9

PMID 31175391

Citations 21

Authors

Giulia Naldini

Chiara Grisci

Manuela Chiavarini

Roberto Fabiani

Affiliations

Soon will be listed here.

Abstract

Objectives: Human papillomavirus (HPV) and chlamydia trachomatis (Ct) infection lead to severe consequences for women's health. This meta-analysis summarizes the evidence on HPV infection risk in women with chlamydia and chlamydia risk in HPV-positive women.

Methods: Medline, Web of Science and Scopus were systematically searched for eligible publications until May 2018. Eligibility criteria included: assessment of HPV/Ct infection; cohort, case-control, cross-sectional study design; and reported risk estimation with its 95% CI for HPV infection in Ct-positive women and/or Ct infection in HPV-positive women. On the PRISMA guidelines, meta-analysis was performed using random effect model.

Results: Forty-eight studies met the eligibility criteria. Among women with chlamydia, the odds ratio (OR) of HPV infection is 2.12 (95% CI 1.80, 2.49) and the OR of high-risk HPV infection is 2.32 (95% CI 2.02, 2.65). The OR for chlamydia among HPV-positive women is 2.23 (95% CI 1.70, 2.92).

Conclusions: HPV and Ct behave as reciprocal risk factors. In women diagnosed with HPV infection or chlamydia, the screening for the mutual infection could represent a preventive intervention for severe reproductive health outcomes, such as cervical cancer and infertility.

Citing Articles

Molecular Detection of Human Papillomavirus (HPV) and Other Sexually Transmitted Pathogens in Cervical and Self-Collected Specimens.

Giubbi C, Martinelli M, Rizza M, Di Meo M, Njoku R, Perdoni F Int J Mol Sci. 2025; 26(3).

PMID: 39941064 PMC: 11818694. DOI: 10.3390/ijms26031296.

The Assessment of Knowledge About Cervical Cancer, HPV Vaccinations, and Screening Programs Among Women as an Element of Cervical Cancer Prevention in Poland.

Wdowiak K, Drab A, Filipek P, Religioni U J Pers Med. 2024; 14(12).

PMID: 39728052 PMC: 11678483. DOI: 10.3390/jpm14121139.

Analysis of risk factors associated with cervical HPV infection and their effects on female sexual function and anxiety: a multicenter cross-sectional study based on Chinese women.

Wang H, Nie K, Liu Z, Zhao Y, Ha Y, Zhang H Front Oncol. 2024; 14:1468160.

PMID: 39512769 PMC: 11540700. DOI: 10.3389/fonc.2024.1468160.

Prevalence of bacterial vaginosis, sexually transmitted infections and their association with HPV infections in asymptomatic women attending antenatal care in Ethiopia.

Klein J, Runge I, Pannen A, Wakuma T, Abera S, Adissie A Ecancermedicalscience. 2024; 18:1783.

PMID: 39430093 PMC: 11489113. DOI: 10.3332/ecancer.2024.1783.

Type-specific human papillomavirus prevalence in women referred for colposcopy in Tehran.

Soleimani-Jelodar R, Arashkia A, Shoja Z, Sharifian K, Akhavan S, Yarandi F Iran J Microbiol. 2024; 16(3):421-427.

PMID: 39005605 PMC: 11245344. DOI: 10.18502/ijm.v16i3.15799.

References

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Tjiong M, Out T, Ter Schegget J, Burger M, van der Vange N . Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review. Int J Gynecol Cancer. 2001; 11(1):9-17. DOI: 10.1046/j.1525-1438.2001.011001009.x. View

Man S, Fiander A . Immunology of human papillomavirus infection in lower genital tract neoplasia. Best Pract Res Clin Obstet Gynaecol. 2001; 15(5):701-14. DOI: 10.1053/beog.2001.0215. View

Giuliano A, Papenfuss M, Abrahamsen M, Denman C, De Zapien J, Henze J . Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev. 2001; 10(11):1129-36. View

Tamim H, Finan R, Sharida H, Rashid M, Almawi W . Cervicovaginal coinfections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis. 2002; 43(4):277-81. DOI: 10.1016/s0732-8893(02)00403-0. View

Giuliano A, Papenfuss M, Abrahamsen M, Inserra P . Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev. 2002; 11(9):930-4. View

Ezzati M, Lopez A, Rodgers A, Vander Hoorn S, Murray C . Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343):1347-60. DOI: 10.1016/S0140-6736(02)11403-6. View

Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T . Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol. 2003; 77(19):10186-201. PMC: 228472. DOI: 10.1128/jvi.77.19.10186-10201.2003. View

Molano M, Weiderpass E, Posso H, Morre S, Ronderos M, Franceschi S . Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. Sex Transm Infect. 2003; 79(6):474-8. PMC: 1744784. DOI: 10.1136/sti.79.6.474. View

10.

Mayaud P, Mabey D . Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect. 2004; 80(3):174-82. PMC: 1744836. DOI: 10.1136/sti.2002.004101. View

11.

da Silva C, Adad S, Hazarabedian de Souza M, Macedo Barcelos A, Terra A, Murta E . Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection. Gynecol Obstet Invest. 2004; 58(4):189-93. DOI: 10.1159/000079822. View

12.

Aral S . Sexual risk behaviour and infection: epidemiological considerations. Sex Transm Infect. 2004; 80 Suppl 2:ii8-12. PMC: 1765854. DOI: 10.1136/sti.2004.011866. View

13.

Golijow C, Abba M, Mouron S, Laguens R, Dulout F, Smith J . Chlamydia trachomatis and Human papillomavirus infections in cervical disease in Argentine women. Gynecol Oncol. 2004; 96(1):181-6. DOI: 10.1016/j.ygyno.2004.09.037. View

14.

Baldwin S, Djambazov B, Papenfuss M, Abrahamsen M, Denman C, Guernsey de Zapien J . Chlamydial infection in women along the US-Mexico border. Int J STD AIDS. 2004; 15(12):815-21. DOI: 10.1258/0956462042563792. View

15.

Watts D, Fazzari M, Fazarri M, Minkoff H, Hillier S, Sha B . Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis. 2005; 191(7):1129-39. DOI: 10.1086/427777. View

16.

Boardman L, Stanko C, Weitzen S, Sung C . Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol. 2005; 105(4):741-6. DOI: 10.1097/01.AOG.0000157126.12678.a6. View

17.

Tabora N, Zelaya A, Bakkers J, Melchers W, Ferrera A . Chlamydia trachomatis and genital human papillomavirus infections in female university students in Honduras. Am J Trop Med Hyg. 2005; 73(1):50-3. View

18.

Zhang B, Chen W, Roman A . The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci U S A. 2005; 103(2):437-42. PMC: 1326189. DOI: 10.1073/pnas.0510012103. View

19.

Finan R, Musharrafieh U, Almawi W . Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect. 2006; 12(9):927-30. DOI: 10.1111/j.1469-0691.2006.01479.x. View

20.

Kanodia S, Fahey L, Kast W . Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007; 7(1):79-89. DOI: 10.2174/156800907780006869. View